|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue (Note 21) | |||||
| Operating expenses | |||||
| Selling, marketing and administration (Note 20) | |||||
| Research and development (Note 20) | |||||
| Operating expenses | |||||
| Operating loss before the following | |||||
| Loss on acquisition of 24.8% of SPX (Note 5) | |||||
| Interest expense (Note 8) | |||||
| Other income, including interest | |||||
| Forgiveness of Covid-19 government support loans (Note 23) | |||||
| Gain on contribution of intellectual property to joint venture (Note 5) | |||||
| Share of loss in joint venture (Note 5) | |||||
| Fair value adjustment to derivative warrant liability (Note 10 and 11(b)) | |||||
| Net loss | |||||
| Deficit, end of year | |||||
| Basic net loss per share (Note 14) | |||||
| Diluted net loss per share (Note 14) | |||||
| Deficit, beginning of year | |||||
| Adjustment due to change in functional currency | |||||
Loading...